Eintrag weiter verarbeiten
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects wi...
Gespeichert in:
Zeitschriftentitel: | Blood |
---|---|
Personen und Körperschaften: | , , , , , , , , , , |
In: | Blood, 106, 2005, 11, S. 2129-2129 |
Format: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
American Society of Hematology
|
Schlagwörter: |
author_facet |
Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. |
---|---|
author |
Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. |
spellingShingle |
Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. Blood Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. Cell Biology Hematology Immunology Biochemistry |
author_sort |
mavromatis, blanche |
spelling |
Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v106.11.2129.2129 <jats:title>Abstract</jats:title> <jats:p>Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL. Genasense (G) enhances apoptosis induced by fludarabine (F), dexamethasone, and rituximab (R) in vitro. Despite limited single-agent activity in heavily pre-treated CLL pts, G significantly increased the rate of durable complete responses (CR) in combination with fludarabine (F) and cyclophosphamide in relapsed or refractory CLL (Rai, ASH 2004). Down-regulation of Bcl-2 sensitizes CLL cells to apoptosis induced by F and R. In order to examine the impact of G on the FR combination, we initiated a phase II study of the combination of FRG in pts with either previously untreated (UT) or relapsed, previously treated (PT) CLL who require systemic treatment. Eligibility includes: plts ≥ 50,000/mm3; serum Cr ≤ 1.5 mg/dL; adequate organ function; negative Coombs; no history of autoimmune hemolytic anemia. In cycle 1, G is given by continuous intravenous infusion at 1.5 mg/kg/d days 1 to 7. R is given in a dose-escalating schema: 125 mg/m2 on day 4 and 250mg/m2 on day 6, with F (25 mg/m2/d) on days 6 to 8. In subsequent 28-day cycles (up to 6), the dose of G is escalated to 3 mg/kg/d days 1 to 7, with R 375 mg/m2 on day 5 and F days 5 to 7.</jats:p> <jats:p>Results: To date, 24 pts have been enrolled (19 PT and 5 UT). Characteristics included: median age, 56.5 yrs (range 25–82 yrs); Rai stage III, 6 pts (4 PT and 2 UT) and IV, 6 pts (6 PT and 0 UT). Median prior regimens (PT pts), 2; 13/19 (68%) had received F and R previously. Median # cycles administered: 6 (both UT and PT). Four PT pts discontinued treatment before completing 6 cycles, 2 due to disease progression, and 2 with prolonged (&gt; 4 week) Grade 3 thrombocytopenia/neutropenia. One PT pt completed only 3 cycles of R due to an R-related infusion reaction, but completed 6 cycles of G and F. Among the 5 UT pts, there was 1 case of grade 4 neutropenia. Among the 19 PT pts, there were 2 cases each of grade 4 thrombocytopenia and neutropenia. One of 5 UT pts had an SAE of reversible acute renal insufficiency. Seven of 19 PT pts (8 events total) experienced an SAE. These included R-related infusion reactions (2 pts), bacteremia (2 pts) and 1 pt each with fever, lymph node abscess, pneumonia, and thrombocytopenia/neutropenia. Responses have been observed in 5/5 UT pts (1 molecular CR (mCR), 1 nPR and 3 PR) and 10/19 PT pts (1 mCR, 2 nPR and 7 PR).</jats:p> <jats:p>Conclusions: 24 pts have been treated with the combination of FRG. Employing a three-day regimen of F, good tolerability and efficacy have been noted in relapsed/refractory patients. Based on these results, an additional cohort receiving a full 5-day regimen of F is ongoing with measurement of Genasense PK and bcl-2 intracellular levels (mRNA and protein).</jats:p> Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. Blood |
doi_str_mv |
10.1182/blood.v106.11.2129.2129 |
facet_avail |
Online Free |
finc_class_facet |
Biologie Medizin Chemie und Pharmazie |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA2LjExLjIxMjkuMjEyOQ |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA2LjExLjIxMjkuMjEyOQ |
institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 |
imprint |
American Society of Hematology, 2005 |
imprint_str_mv |
American Society of Hematology, 2005 |
issn |
0006-4971 1528-0020 |
issn_str_mv |
0006-4971 1528-0020 |
language |
English |
mega_collection |
American Society of Hematology (CrossRef) |
match_str |
mavromatis2005efficacyandsafetyofthecombinationofgenasenseoblimersensodiumbcl2antisenseoligonucleotidefludarabineandrituximabinpreviouslytreatedanduntreatedsubjectswithchroniclymphocyticleukemia |
publishDateSort |
2005 |
publisher |
American Society of Hematology |
recordtype |
ai |
record_format |
ai |
series |
Blood |
source_id |
49 |
title |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_unstemmed |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_full |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_fullStr |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_full_unstemmed |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_short |
Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_sort |
efficacy and safety of the combination of genasense™ (oblimersen sodium, bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. |
topic |
Cell Biology Hematology Immunology Biochemistry |
url |
http://dx.doi.org/10.1182/blood.v106.11.2129.2129 |
publishDate |
2005 |
physical |
2129-2129 |
description |
<jats:title>Abstract</jats:title>
<jats:p>Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL. Genasense (G) enhances apoptosis induced by fludarabine (F), dexamethasone, and rituximab (R) in vitro. Despite limited single-agent activity in heavily pre-treated CLL pts, G significantly increased the rate of durable complete responses (CR) in combination with fludarabine (F) and cyclophosphamide in relapsed or refractory CLL (Rai, ASH 2004). Down-regulation of Bcl-2 sensitizes CLL cells to apoptosis induced by F and R. In order to examine the impact of G on the FR combination, we initiated a phase II study of the combination of FRG in pts with either previously untreated (UT) or relapsed, previously treated (PT) CLL who require systemic treatment. Eligibility includes: plts ≥ 50,000/mm3; serum Cr ≤ 1.5 mg/dL; adequate organ function; negative Coombs; no history of autoimmune hemolytic anemia. In cycle 1, G is given by continuous intravenous infusion at 1.5 mg/kg/d days 1 to 7. R is given in a dose-escalating schema: 125 mg/m2 on day 4 and 250mg/m2 on day 6, with F (25 mg/m2/d) on days 6 to 8. In subsequent 28-day cycles (up to 6), the dose of G is escalated to 3 mg/kg/d days 1 to 7, with R 375 mg/m2 on day 5 and F days 5 to 7.</jats:p>
<jats:p>Results: To date, 24 pts have been enrolled (19 PT and 5 UT). Characteristics included: median age, 56.5 yrs (range 25–82 yrs); Rai stage III, 6 pts (4 PT and 2 UT) and IV, 6 pts (6 PT and 0 UT). Median prior regimens (PT pts), 2; 13/19 (68%) had received F and R previously. Median # cycles administered: 6 (both UT and PT). Four PT pts discontinued treatment before completing 6 cycles, 2 due to disease progression, and 2 with prolonged (&gt; 4 week) Grade 3 thrombocytopenia/neutropenia. One PT pt completed only 3 cycles of R due to an R-related infusion reaction, but completed 6 cycles of G and F. Among the 5 UT pts, there was 1 case of grade 4 neutropenia. Among the 19 PT pts, there were 2 cases each of grade 4 thrombocytopenia and neutropenia. One of 5 UT pts had an SAE of reversible acute renal insufficiency. Seven of 19 PT pts (8 events total) experienced an SAE. These included R-related infusion reactions (2 pts), bacteremia (2 pts) and 1 pt each with fever, lymph node abscess, pneumonia, and thrombocytopenia/neutropenia. Responses have been observed in 5/5 UT pts (1 molecular CR (mCR), 1 nPR and 3 PR) and 10/19 PT pts (1 mCR, 2 nPR and 7 PR).</jats:p>
<jats:p>Conclusions: 24 pts have been treated with the combination of FRG. Employing a three-day regimen of F, good tolerability and efficacy have been noted in relapsed/refractory patients. Based on these results, an additional cohort receiving a full 5-day regimen of F is ongoing with measurement of Genasense PK and bcl-2 intracellular levels (mRNA and protein).</jats:p> |
container_issue |
11 |
container_start_page |
2129 |
container_title |
Blood |
container_volume |
106 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792332490556309505 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T13:57:39.868Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Efficacy+and+Safety+of+the+Combination+of+Genasense%E2%84%A2+%28Oblimersen+Sodium%2C+Bcl-2+Antisense+Oligonucleotide%29%2C+Fludarabine+and+Rituximab+in+Previously+Treated+and+Untreated+Subjects+with+Chronic+Lymphocytic+Leukemia.&rft.date=2005-11-16&genre=article&issn=1528-0020&volume=106&issue=11&spage=2129&epage=2129&pages=2129-2129&jtitle=Blood&atitle=Efficacy+and+Safety+of+the+Combination+of+Genasense%E2%84%A2+%28Oblimersen+Sodium%2C+Bcl-2+Antisense+Oligonucleotide%29%2C+Fludarabine+and+Rituximab+in+Previously+Treated+and+Untreated+Subjects+with+Chronic+Lymphocytic+Leukemia.&aulast=Chanan-Khan&aufirst=Asher+A.&rft_id=info%3Adoi%2F10.1182%2Fblood.v106.11.2129.2129&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792332490556309505 |
author | Mavromatis, Blanche, Rai, Kanti R., Wallace, Paul K., Soho, Claudia, Landrigan, Beverly, Meyn, Patricia, Wei, Tracey, Chan, Kenneth K., Casey, Philomena, Novick, Steven C., Chanan-Khan, Asher A. |
author_facet | Mavromatis, Blanche, Rai, Kanti R., Wallace, Paul K., Soho, Claudia, Landrigan, Beverly, Meyn, Patricia, Wei, Tracey, Chan, Kenneth K., Casey, Philomena, Novick, Steven C., Chanan-Khan, Asher A., Mavromatis, Blanche, Rai, Kanti R., Wallace, Paul K., Soho, Claudia, Landrigan, Beverly, Meyn, Patricia, Wei, Tracey, Chan, Kenneth K., Casey, Philomena, Novick, Steven C., Chanan-Khan, Asher A. |
author_sort | mavromatis, blanche |
container_issue | 11 |
container_start_page | 2129 |
container_title | Blood |
container_volume | 106 |
description | <jats:title>Abstract</jats:title> <jats:p>Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL. Genasense (G) enhances apoptosis induced by fludarabine (F), dexamethasone, and rituximab (R) in vitro. Despite limited single-agent activity in heavily pre-treated CLL pts, G significantly increased the rate of durable complete responses (CR) in combination with fludarabine (F) and cyclophosphamide in relapsed or refractory CLL (Rai, ASH 2004). Down-regulation of Bcl-2 sensitizes CLL cells to apoptosis induced by F and R. In order to examine the impact of G on the FR combination, we initiated a phase II study of the combination of FRG in pts with either previously untreated (UT) or relapsed, previously treated (PT) CLL who require systemic treatment. Eligibility includes: plts ≥ 50,000/mm3; serum Cr ≤ 1.5 mg/dL; adequate organ function; negative Coombs; no history of autoimmune hemolytic anemia. In cycle 1, G is given by continuous intravenous infusion at 1.5 mg/kg/d days 1 to 7. R is given in a dose-escalating schema: 125 mg/m2 on day 4 and 250mg/m2 on day 6, with F (25 mg/m2/d) on days 6 to 8. In subsequent 28-day cycles (up to 6), the dose of G is escalated to 3 mg/kg/d days 1 to 7, with R 375 mg/m2 on day 5 and F days 5 to 7.</jats:p> <jats:p>Results: To date, 24 pts have been enrolled (19 PT and 5 UT). Characteristics included: median age, 56.5 yrs (range 25–82 yrs); Rai stage III, 6 pts (4 PT and 2 UT) and IV, 6 pts (6 PT and 0 UT). Median prior regimens (PT pts), 2; 13/19 (68%) had received F and R previously. Median # cycles administered: 6 (both UT and PT). Four PT pts discontinued treatment before completing 6 cycles, 2 due to disease progression, and 2 with prolonged (&gt; 4 week) Grade 3 thrombocytopenia/neutropenia. One PT pt completed only 3 cycles of R due to an R-related infusion reaction, but completed 6 cycles of G and F. Among the 5 UT pts, there was 1 case of grade 4 neutropenia. Among the 19 PT pts, there were 2 cases each of grade 4 thrombocytopenia and neutropenia. One of 5 UT pts had an SAE of reversible acute renal insufficiency. Seven of 19 PT pts (8 events total) experienced an SAE. These included R-related infusion reactions (2 pts), bacteremia (2 pts) and 1 pt each with fever, lymph node abscess, pneumonia, and thrombocytopenia/neutropenia. Responses have been observed in 5/5 UT pts (1 molecular CR (mCR), 1 nPR and 3 PR) and 10/19 PT pts (1 mCR, 2 nPR and 7 PR).</jats:p> <jats:p>Conclusions: 24 pts have been treated with the combination of FRG. Employing a three-day regimen of F, good tolerability and efficacy have been noted in relapsed/refractory patients. Based on these results, an additional cohort receiving a full 5-day regimen of F is ongoing with measurement of Genasense PK and bcl-2 intracellular levels (mRNA and protein).</jats:p> |
doi_str_mv | 10.1182/blood.v106.11.2129.2129 |
facet_avail | Online, Free |
finc_class_facet | Biologie, Medizin, Chemie und Pharmazie |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTA2LjExLjIxMjkuMjEyOQ |
imprint | American Society of Hematology, 2005 |
imprint_str_mv | American Society of Hematology, 2005 |
institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2 |
issn | 0006-4971, 1528-0020 |
issn_str_mv | 0006-4971, 1528-0020 |
language | English |
last_indexed | 2024-03-01T13:57:39.868Z |
match_str | mavromatis2005efficacyandsafetyofthecombinationofgenasenseoblimersensodiumbcl2antisenseoligonucleotidefludarabineandrituximabinpreviouslytreatedanduntreatedsubjectswithchroniclymphocyticleukemia |
mega_collection | American Society of Hematology (CrossRef) |
physical | 2129-2129 |
publishDate | 2005 |
publishDateSort | 2005 |
publisher | American Society of Hematology |
record_format | ai |
recordtype | ai |
series | Blood |
source_id | 49 |
spelling | Mavromatis, Blanche Rai, Kanti R. Wallace, Paul K. Soho, Claudia Landrigan, Beverly Meyn, Patricia Wei, Tracey Chan, Kenneth K. Casey, Philomena Novick, Steven C. Chanan-Khan, Asher A. 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v106.11.2129.2129 <jats:title>Abstract</jats:title> <jats:p>Bcl-2 is an anti-apoptotic protein closely linked to chemotherapy resistance and inferior survival in patients (pts) with CLL. Genasense (G) enhances apoptosis induced by fludarabine (F), dexamethasone, and rituximab (R) in vitro. Despite limited single-agent activity in heavily pre-treated CLL pts, G significantly increased the rate of durable complete responses (CR) in combination with fludarabine (F) and cyclophosphamide in relapsed or refractory CLL (Rai, ASH 2004). Down-regulation of Bcl-2 sensitizes CLL cells to apoptosis induced by F and R. In order to examine the impact of G on the FR combination, we initiated a phase II study of the combination of FRG in pts with either previously untreated (UT) or relapsed, previously treated (PT) CLL who require systemic treatment. Eligibility includes: plts ≥ 50,000/mm3; serum Cr ≤ 1.5 mg/dL; adequate organ function; negative Coombs; no history of autoimmune hemolytic anemia. In cycle 1, G is given by continuous intravenous infusion at 1.5 mg/kg/d days 1 to 7. R is given in a dose-escalating schema: 125 mg/m2 on day 4 and 250mg/m2 on day 6, with F (25 mg/m2/d) on days 6 to 8. In subsequent 28-day cycles (up to 6), the dose of G is escalated to 3 mg/kg/d days 1 to 7, with R 375 mg/m2 on day 5 and F days 5 to 7.</jats:p> <jats:p>Results: To date, 24 pts have been enrolled (19 PT and 5 UT). Characteristics included: median age, 56.5 yrs (range 25–82 yrs); Rai stage III, 6 pts (4 PT and 2 UT) and IV, 6 pts (6 PT and 0 UT). Median prior regimens (PT pts), 2; 13/19 (68%) had received F and R previously. Median # cycles administered: 6 (both UT and PT). Four PT pts discontinued treatment before completing 6 cycles, 2 due to disease progression, and 2 with prolonged (&gt; 4 week) Grade 3 thrombocytopenia/neutropenia. One PT pt completed only 3 cycles of R due to an R-related infusion reaction, but completed 6 cycles of G and F. Among the 5 UT pts, there was 1 case of grade 4 neutropenia. Among the 19 PT pts, there were 2 cases each of grade 4 thrombocytopenia and neutropenia. One of 5 UT pts had an SAE of reversible acute renal insufficiency. Seven of 19 PT pts (8 events total) experienced an SAE. These included R-related infusion reactions (2 pts), bacteremia (2 pts) and 1 pt each with fever, lymph node abscess, pneumonia, and thrombocytopenia/neutropenia. Responses have been observed in 5/5 UT pts (1 molecular CR (mCR), 1 nPR and 3 PR) and 10/19 PT pts (1 mCR, 2 nPR and 7 PR).</jats:p> <jats:p>Conclusions: 24 pts have been treated with the combination of FRG. Employing a three-day regimen of F, good tolerability and efficacy have been noted in relapsed/refractory patients. Based on these results, an additional cohort receiving a full 5-day regimen of F is ongoing with measurement of Genasense PK and bcl-2 intracellular levels (mRNA and protein).</jats:p> Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. Blood |
spellingShingle | Mavromatis, Blanche, Rai, Kanti R., Wallace, Paul K., Soho, Claudia, Landrigan, Beverly, Meyn, Patricia, Wei, Tracey, Chan, Kenneth K., Casey, Philomena, Novick, Steven C., Chanan-Khan, Asher A., Blood, Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia., Cell Biology, Hematology, Immunology, Biochemistry |
title | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_full | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_fullStr | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_full_unstemmed | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_short | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
title_sort | efficacy and safety of the combination of genasense™ (oblimersen sodium, bcl-2 antisense oligonucleotide), fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. |
title_unstemmed | Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia. |
topic | Cell Biology, Hematology, Immunology, Biochemistry |
url | http://dx.doi.org/10.1182/blood.v106.11.2129.2129 |